Depixus, a pioneering intereactomics company, has been awarded the prestigious Ignite Award from the Society for Laboratory Automation and Screening (SLAS) at their annual International Conference and Exhibition in Boston, MA. This recognition comes after Depixus unveiled their groundbreaking MAGNA One™ instrument at the conference, which utilizes magnetic force spectroscopy to enable high-throughput analysis of dynamic biomolecular interactions.
The Ignite Award is given to companies that are revolutionizing the life sciences with their innovative technologies. Depixus was one of 16 companies selected to participate in the SLAS2024 Innovation AveNEW program, which is a dedicated area for start-ups and emerging companies within the conference. From this group of 16 companies, Depixus was chosen as one of the top eight finalists for the Ignite Award.
MAGNA One provides valuable insights into disease mechanisms by allowing real-time measurements from thousands of individual molecules simultaneously. This technology is particularly useful for exploring challenging targets such as RNA and protein-protein interactions. It accelerates the development of novel therapeutics by providing high-throughput analysis of dynamic biomolecular interactions.
Gordon Hamilton, CEO of Depixus, expressed his excitement about winning the Ignite Award, emphasizing the company’s innovative technology and its potential to impact the understanding and treatment of diseases where new treatments are urgently needed. Steve Klose, Chief Commercial Officer at Depixus added that this timing coincides perfectly with their technology access program launch and commercial rollout of MAGNA One, marking a significant moment for the company.
For more information about Depixus and their products, visit depixus.com or contact Steve Klose at firstname.lastname@example.org.